Sparking Transformation in Healthcare
egnite is a company with a vision:
to identify and improve outcomes for every cardiovascular patient in the U.S.
Sparking Transformation in Healthcare
egnite is a company with a vision:
to identify and improve outcomes for every cardiovascular patient in the U.S.
Using Big Data to Solve Big Problems 
Advancing the Cardiovascular Health of Our Society
egnite is a digital health company leveraging artificial intelligence-driven algorithms to produce business intelligence for healthcare, elevating the role of data in critical decisions.
FOR HEALTH PROFESSIONALS
The CardioCare Platform
by artificial intelligence
FOR LIFE SCIENCES 
egnite Therapy Accelerator & Research
of real-world cardiovascular data
Podcasts
egnite COO, Jessica Neufeld, discusses the current state of A.I. adoption and challenges in healthcare, along with the role of technology in improving patient care on a recent episode of Microsoft’s Data and A.I. podcast Insights Tomorrow.
egnite Senior Medical Advisor, Rahul Sharma, was recently featured on MedAxiom’s HeartTalk podcast to discuss how technology can be used to identify and treat patients before it’s too late.
Learn more from egnite CEO, Joel Portice, on how egnite is elevating the role of A.I. and big data to guide critical decisions in healthcare on Mike Moore’s The Bleeding Edge of Digital Health podcast.
Presented or Published in
Recognition
Testimonials
Leading health systems and life sciences organizations partner with egnite to transform care delivery for cardiovascular patients.
Gagnon Cardiovascular Institute, Morristown Medical Center
Director of Structural Interventions, Stanford Health Care
Senior Medical Advisor, egnite
Resources
CASE STUDY: Leveraging CardioCare to Get with the Guidelines
Reducing variability in care for this patient population is critical to early identification and improving patient outcomes...
CASE STUDY: Driving Better Outcomes Through Targeted Patient Identification
Reducing variability in care for this patient population is critical to early identification and improving patient outcomes...
What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams
On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.